Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

  1. Coles, A.J.
  2. Jones, J.L.
  3. Vermersch, P.
  4. Traboulsee, A.
  5. Bass, A.D.
  6. Boster, A.
  7. Chan, A.
  8. Comi, G.
  9. Fernández, Ó.
  10. Giovannoni, G.
  11. Kubala Havrdova, E.
  12. LaGanke, C.
  13. Montalban, X.
  14. Oreja-Guevara, C.
  15. Piehl, F.
  16. Wiendl, H.
  17. Ziemssen, T.
Aldizkaria:
Multiple Sclerosis Journal

ISSN: 1477-0970,  1352-4585

Argitalpen urtea: 2022

Alea: 28

Zenbakia: 5

Orrialdeak: 842-846

Mota: Artikulua

DOI: 10.1177/13524585211061335 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus